List of Tykerb drug patents

Tykerb is owned by Novartis.

Tykerb contains Lapatinib Ditosylate.

Tykerb has a total of 1 drug patent out of which 0 drug patents have expired.

Tykerb was authorised for market use on 13 March, 2007.

Tykerb is available in tablet;oral dosage forms.

The generics of Tykerb are possible to be released after 18 September, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8821927 NOVARTIS Pharmaceutical composition
Sep, 2029

(6 years from now)

Drugs and Companies using LAPATINIB DITOSYLATE ingredient

Market Authorisation Date: 13 March, 2007

Treatment: NA


How can I launch a generic of TYKERB before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in